- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Adello Biologics Submits BLA for Filgrastim Biosimilar
Adello Biologics, a New Jersey-based biosimilar developer previously named Therapeutic Proteins International, announced this week that its Biologics License Application (BLA) for a biosimilar filgrastim candidate has been accepted for review by the FDA.
Adello Biologics, a New Jersey-based biosimilar developer previously named Therapeutic Proteins International, announced this week that its Biologics License Application (BLA) for a biosimilar filgrastim candidate has been accepted for review by the FDA. The company did not disclose a biosimilar user fee action date for a regulatory decision by the FDA.
Peter Moesta, PhD, CEO of Adello said, “If approved, we are excited to be able to offer an additional, important treatment choice that can prevent serious complications for patients.”
Adello’s BLA includes data from a double-blind, single-dose, 2-period crossover pharmacokinetic (PK) and pharmacodynamic (PD) study of its product in comparison with the reference filgrastim. The study, which included 54 healthy volunteers, demonstrated that Adello’s product had similar PK and PD properties to the reference drug. Safety and immunogenicity were also similar between the 2 products.
Reference filgrastim (Amgen’s Neupogen) is a granulocyte colony-stimulating factor used to treat or prevent chemotherapy-induced neutropenia. To date, 1 biosimilar filgrastim, Sandoz’s Zarxio, is available in the United States.
Adello also reported that it is developing a biosimilar pegfilgrastim, referenced on Neulasta, and a biosimilar adalimumab, referenced on Humira, in addition to a number of other products that are currently in preclinical development.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
August 2nd 2025On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
August 2nd 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
August 2nd 2025On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
August 2nd 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Targeted Reimbursement Encourages Oncology Biosimilar Use
August 2nd 2025Incentivizing physicians with modest financial bonuses may seem like a small step, but in Japan’s outpatient oncology setting, it helped push trastuzumab biosimilars toward broader adoption, demonstrating how even limited reimbursement reforms can reshape prescribing behavior under the right conditions.
